Date:6/28/2010

Analysis 68 10 Global GERD Therapeutics Market 69 10.1 Market Overview 69 10.2 Market Forecasts 69 10.3 Annual Cost of Treatment 71 10.4 Usage Patterns 72 10.4.1 Diseased Population 72 10.4.2 Treatment Seeking Population 73 10.4.3 Diagnosis Population 74 10.4.4 Prescription Population 75 10.4.5 Threapy Usage Patterns 76 10.5 Product Analysis 77 10.5.1 Nexium (esomeprazole) 77 10.5.2 Aciphex (rabeprazole sodium) 77 10.5.3 Prevacid (lansoprazole) 77 10.5.4 Prilosec (omeprazole) 78 10.5.5 Protonix (pantoprazole sodium) 78 10.5.6 Tagamet (cimetidine) 78 10.5.7 Pepcid (famotidine) 78 10.5.8 Zantac (ranitidine hydrochloride) 78 10.5.9 Axid (nizatidine) 78 10.6 Drug Pipeline Analysis 79 11 Global Crohn's Disease Therapeutics Market 80 11.1 Market Overview 80 11.2 Market Forecasts 81 11.3 Annual Cost of Treatment 82 11.4 Usage Patterns 83 11.4.1 Diseased Population 83 11.4.2 Treatment Seeking Population 84 11.4.3 Diagnosis Population 86 11.4.4 Prescription Population 87 11.4.5 Therapy Usage Patterns 88 11.5 Product Analysis 89 11.5.1 Entocort EC (budenoside) 90 11.5.2 Humira (adalimumab) 90 11.5.3 Tysabri (natalizumab) 90 11.5.4 Remicade (infliximab) 90 11.5.5 Cimzia (cetrolizumab pegol) 91 11.6 Drug Pipeline Analysis 91 12 Global Gastrointestinal Disorder Therapeutics Market: Market Drivers and Restraints 92 12.1 Market Drivers 92 12.1.1 Steady Increase in the Elderly Population 93 12.1.2 Stable Increase in Incidence Rates for Gastrointestinal Disorders 93 12.1.3 Increase in Awareness Levels of Disease Progression and Etiology 93 12.2 Market Restraints 93 12.2.1 Entry of Generics Pose a Serious Problem for Primary Manufacturers 94 12.2.2 Presence of Serious Side Effects for Certain Classes of Therapeutic Drugs 94 13 Global Gastrointestinal Disorder Therapeutics Market
'/>"/>

SOURCE MarketsandMarkets Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Related biology technology :

1. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
2. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
3. Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
4. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
5. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
6. New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinsons Disease
7. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
8. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
9. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
10. SleepQuest Raises Awareness of Sleep Disorders
11. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders